Bristol Myers Squibb plaque psoriasis drug Sotyktu will be the first product available at a steep discount to eligible cash-pay patients who use BMS Patient Connect, a new online platform set to launch in January. Direct-to-patient sales could offer one way for pharma companies to address President Trump’s call for lower drug prices.
The post Immunology Drug Sotyktu Will Kick Off Bristol Myers Squibb’s New Direct-to-Patient Platform appeared first on MedCity News.
